Company: INSP
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001609550-25-000053
Chunk: 56

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 56
---
 taxes3,619 1,829 1,790 97.9 %6,046 3,532 2,514 71.2 %Net income$9,932 $18,497 $(8,565)(46.3)%$9,332 $18,285 $(8,953)(49.0)%

Comparison of the Three Months Ended September 30, 2025 and 2024

Revenue

Revenue increased $21.3 million, or 10.5%, to $224.5 million for the three months ended September 30, 2025 compared to $203.2 million for the three months ended September 30, 2024. These results reflect an increase in sales of our Inspire system of $18.6 million in the U.S. and an increase of $2.7 million outside of the U.S. compared to the same prior year period. Overall revenue growth was primarily due to increased market penetration, and, we believe, increased physician and patient awareness of our Inspire system, partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.

Revenue information by region is summarized as follows:Three Months Ended September 30,20252024ChangeAmount% of RevenueAmount% of Revenue$%(in thousands, except percentages)United States$214,394 95.5 %$195,828 96.4 %$18,566 9.5 %All other countries10,107 4.5 %7,363 3.6 %2,744 37.3 %Total revenue$224,501 100.0 %$203,191 100.0 %$21,310 10.5 %

Revenue generated in the U.S. was $214.4 million for the three months ended September 30, 2025, an increase of $18.6 million, or 9.5%, compared to the three months ended September 30, 2024. Revenue growth in the U.S. was primarily due to increased market penetration, and, we believe, increased physician and patient awareness of our 

34

Inspire system, partially offset by ENT surgeon capacity constraints and some patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications